Carolyn Majcher, OD, FAAO, describes challenges primary eye care providers can experience when diagnosing diabetic retinopathy and diabetic macular edema (DR/DME).

Diabetic retinal disease experts discuss the standard diagnostic imaging tools that are available to detect diabetic retinopathy and diabetic macular edema (DR/DME).

Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, took the podium at the New Horizons Forum at the Glaucoma 360 conference in San Francisco to discuss the performance of the company’s episcleral venous pressure eyedrop, QLS-111.

Kristen H. Ingenito, MBA, vice president and director of ophthalmics at Market Scope, discusses the volume of ophthalmologists offering interventional glaucoma treatment as well as emerging therapies in her presentation at the Glaucoma 360 New Horizons Forum.

The Phase 2 SPECTRA clinical trial will assess 4D-150 in patients with DME.

According to the indictment, beginning in June 2017, Anthony David Flores and Anna Rene Moore used false promises and representations to befriend the victim — an ophthalmologist and successful investor worth more than $60 million.

The results are consistent with those observed, and previously published by the same group, showing benefit in age related macular degeneration models and highlights the potential value of ophNdi1 for multiple eye diseases.

Over the years, IKA has become an invaluable resource for eye care professionals.

The company noted that the product is a sterile, single-patient use, physician administered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia.

The vision care company is joining forces with the global nonprofit to fight avoidable blindness around the world.

According to the company, ONL1204 is a first-in-class small molecule Fas inhibitor with a mechanism of action designed to provide neuroprotection for retinal cells.

Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.

The Bascom Palmer program showcases neovascular, exudative, and degenerative eye diseases, and is designed for retina specialists, general ophthalmologists and researchers.

In a news release, the CDC is urging that clinicians and patients immediately discontinue the use of EzriCare Artificial Tears until the epidemiological investigation and laboratory analyses are complete.

A leader in the field of ophthalmology, Cynthia Matossian, MD, FACS, ABES, discusses her career as she prepares for the next phase.

Effective networking involves developing relationships with other people, sharing relevant information and resources, and providing mutual support and encouragement on the path to reaching your goals.